Condition (MeSH)
Perivascular Epithelioid Cell Neoplasms
ClinicalTrials.gov lists 69 trials for Perivascular Epithelioid Cell Neoplasms or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
14 of the 69 trials are tagged with Perivascular Epithelioid Cell Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Perivascular Epithelioid Cell Neoplasms trials start? (27)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 6 |
| 2018 | 6 |
| 2017 | 4 |
Showing 10 of 27 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 35 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Perivascular Epithelioid Cell Neoplasms trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 7 |
| Phase 2 | 17 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Phase 4 | 4 |
| Not applicable | 7 |
| Observational | 23 |
| Expanded access | 1 |
How many Perivascular Epithelioid Cell Neoplasms trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 14 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 7 |
| Completed | 35 |
| Approved for marketing | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Perivascular Epithelioid Cell Neoplasms trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 8 |
| Novartis Pharmaceuticals | 5 |
| Aadi Bioscience, Inc. | 2 |
| National Cancer Institute (NCI) | 2 |
| Biorek S.R.L. | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Perivascular Epithelioid Cell Neoplasms? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sirolimus | 8 |
| EVEROLIMUS | 6 |
| NIVOLUMAB | 2 |
| Imatinib | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ifosfamid | 1 |
| Ivocizumab | 1 |
| L01XE31 - Nintedanib | 1 |
| Nab-Sirolimus | 1 |
| Letrozol (Femara, Novartis) | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Perivascular Epithelioid Cell Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutrophil count decreased | 37 | 2 |
| Febrile neutropenia | 22 | 2 |
| Pulmonary | 15 | 1 |
| Platelet count decreased | 10 | 2 |
| Mucositis oral | 9 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Perivascular Epithelioid Cell Neoplasms? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Phase II Trial of <i>nab-</i>Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | Yes |
| <i>nab</i>-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021 | Yes |
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Perivascular epithelioid cell neoplasm | Annual incidence | Unknown | Worldwide | Not stated | Exact |
| Perivascular epithelioid cell neoplasm | Annual incidence | Unknown | Worldwide | Not stated | Exact |
| Perivascular epithelioid cell neoplasm | Annual incidence | Unknown | Worldwide | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Perivascular epithelioid cell neoplasm | 595133 | Exact | Orphadata Science knowledge files, Product 1 |
| Perivascular epithelioid cell neoplasm | 595133 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.